Skip to content

Study · Not a test of the peptide alone · 2026

4 results

Energy-Metabolism-Enhancing Probiotics Enhance the Therapeutic Response to a Glucagon-like Peptide-1 Receptor Agonist.

Kim AR, Jeon SG, Park SJ, Kim BK, Kweon MN, Jang MH, Yang BG

Nutrients26 Mar 2026Cited by 1 (Europe PMC)

PMID41978101 (opens in a new tab)PMCIDPMC13074448 (opens in a new tab)DOI10.3390/nu18071050 (opens in a new tab)PepBankPUB-41978101
Download PDFPubMedAsk about this study
Jump to 4 results

Summary

Background/Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective treatments for obesity, but substantial weight regain is common after therapy is discontinued. This study investigated whether probiotic strains with anti-obesity effects could enhance GLP-1RA-induced weight loss and attenuate post-treatment weight rebound. Methods: Candidate lactic acid bacteria were screened for anti-obesity efficacy in a high-fat-diet (HFD)-induced obese mouse model, and the selected strain was further characterized using metabolomic profiling of culture supernatants. To examine its interaction with GLP-1RA therapy, obese mice received dulaglutide for 4 weeks and were monitored for 2 weeks after treatment withdrawal, while the probiotic was orally administered for a total of 6 weeks. Body weight, glycemic parameters, and muscle strength were assessed throughout the study. Results: Limosilactobacillus fermentum GB102 reduced body weight and improved glycemic control in HFD-fed mice. These metabolic benefits were associated with alterations in circulating metabolic hormones, including adipokines, along with attenuated inflammatory responses in adipose tissue. Metabolomic profiling revealed that GB102 produced high levels of succinic acid, a metabolite previously linked to thermogenic activation. This strain increased whole-body energy expenditure in HFD-fed mice, produced glutamine, and showed enhanced conversion of arginine into ornithine and citrulline. When combined with dulaglutide, GB102 enhanced weight loss, preserved muscle strength, and attenuated both weight regain and glycemic rebound following dulaglutide withdrawal. Conclusions: These findings suggest that energy-metabolism-enhancing probiotics such as GB102 may enhance the metabolic effects of GLP-1RA therapy and help attenuate weight regain after treatment discontinuation.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

  1. 01AnimalNot a test of Dulaglutide (Trulicity) aloneAnimal study (in vivo)Efficacy outcome

    In obese mice, GB102 combined with dulaglutide enhanced weight loss.

    In plain wordsIn mice with obesity, GB102 combined with dulaglutide increased weight loss.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseWeight loss with GB102 plus dulaglutide
    Study

    mousen: not reported in source

    High-fat-diet-induced obesity
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    When combined with dulaglutide, GB102 enhanced weight loss, preserved muscle strength, and attenuated both weight regain and glycemic rebound following dulaglutide withdrawal.
    2 context sentences
    Summary · context
    Candidate lactic acid bacteria were screened for anti-obesity efficacy in a high-fat-diet (HFD)-induced obese mouse model, and the selected strain was further characterized using metabolomic profiling of culture supernatants.
    Summary · context
    To examine its interaction with GLP-1RA therapy, obese mice received dulaglutide for 4 weeks and were monitored for 2 weeks after treatment withdrawal, while the probiotic was orally administered for a total of 6 weeks.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  2. 02AnimalNot a test of Dulaglutide (Trulicity) aloneAnimal study (in vivo)Efficacy outcome

    In obese mice, GB102 combined with dulaglutide preserved muscle strength.

    In plain wordsIn mice with obesity, GB102 combined with dulaglutide preserved muscle strength.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableMuscle strength with GB102 plus dulaglutide
    Study

    mousen: not reported in source

    High-fat-diet-induced obesity
    Outcome group
    Exercise and physical function · Musculoskeletal

    Source sentences

    Summary
    When combined with dulaglutide, GB102 enhanced weight loss, preserved muscle strength, and attenuated both weight regain and glycemic rebound following dulaglutide withdrawal.
    2 context sentences
    Summary · context
    Candidate lactic acid bacteria were screened for anti-obesity efficacy in a high-fat-diet (HFD)-induced obese mouse model, and the selected strain was further characterized using metabolomic profiling of culture supernatants.
    Summary · context
    To examine its interaction with GLP-1RA therapy, obese mice received dulaglutide for 4 weeks and were monitored for 2 weeks after treatment withdrawal, while the probiotic was orally administered for a total of 6 weeks.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  3. 03AnimalNot a test of Dulaglutide (Trulicity) aloneAnimal study (in vivo)Efficacy outcome

    In obese mice, GB102 combined with dulaglutide attenuated weight regain after dulaglutide withdrawal.

    In plain wordsIn mice with obesity, GB102 combined with dulaglutide reduced weight regain after dulaglutide stopped.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseWeight regain after dulaglutide withdrawal
    Study

    mousen: not reported in source

    High-fat-diet-induced obesity
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    When combined with dulaglutide, GB102 enhanced weight loss, preserved muscle strength, and attenuated both weight regain and glycemic rebound following dulaglutide withdrawal.
    2 context sentences
    Summary · context
    Candidate lactic acid bacteria were screened for anti-obesity efficacy in a high-fat-diet (HFD)-induced obese mouse model, and the selected strain was further characterized using metabolomic profiling of culture supernatants.
    Summary · context
    To examine its interaction with GLP-1RA therapy, obese mice received dulaglutide for 4 weeks and were monitored for 2 weeks after treatment withdrawal, while the probiotic was orally administered for a total of 6 weeks.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  4. 04AnimalNot a test of Dulaglutide (Trulicity) aloneAnimal study (in vivo)Efficacy outcome

    In obese mice, GB102 combined with dulaglutide attenuated glycemic rebound after dulaglutide withdrawal.

    In plain wordsIn mice with obesity, GB102 combined with dulaglutide reduced blood sugar rebound after dulaglutide stopped.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseGlycemic rebound after dulaglutide withdrawal
    Study

    mousen: not reported in source

    High-fat-diet-induced obesity
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    When combined with dulaglutide, GB102 enhanced weight loss, preserved muscle strength, and attenuated both weight regain and glycemic rebound following dulaglutide withdrawal.
    2 context sentences
    Summary · context
    Candidate lactic acid bacteria were screened for anti-obesity efficacy in a high-fat-diet (HFD)-induced obese mouse model, and the selected strain was further characterized using metabolomic profiling of culture supernatants.
    Summary · context
    To examine its interaction with GLP-1RA therapy, obese mice received dulaglutide for 4 weeks and were monitored for 2 weeks after treatment withdrawal, while the probiotic was orally administered for a total of 6 weeks.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.